Pregnancy-associated plasma protein-A (PAPPA), also known as pappalysin, is a member of the insulin-like growth factor (IGF) family. PAPPA acts as a protease, cleaving IGF inhibitors, i.e., IGF binding proteins (IGFBPs), thereby setting free IGFs. The insulin/IGF-axis is involved in cancer in general and in Ewing sarcoma (ES) in particular. ES is a highly malignant bone tumor characterized by early metastatic spread. PAPPA is associated with various cancers. It is overexpressed and required for proliferation in ES. PAPPA also stimulates normal bone growth. We isolated HLA-A In summary, we demonstrate that PAPPA is a first-rate target for TCR-based immunotherapy of ES.
Introduction
Insulin and insulin-like growth factor (IGF) pathways are involved in cancer of both children and adults. In adults, insulin signaling represents a key mechanisms linking obesity and cancer, 1 whereas in childhood the IGF axis is involved in the nexus between birth weight and cancer. 2 Moreover, pregnancy-associated glycosaminoglycan-mediated mechanisms of invasion and growth have recently gained attention as potent therapeutic targets in cancer. 3 Pregnancy-associated plasma protein-A (PAPPA) also known as pappalysin was first described as a circulating protein during pregnancy and has been associated with breast, ovarian, renal, gastric and lung cancer, as well as pleural mesothelioma. [4] [5] [6] [7] [8] [9] [10] More than a decade ago, we had identified PAPPA as being overexpressed in primary Ewing sarcoma (ES) and metastases 11 -to our knowledge the first description of PAPPA in association with a mesenchymal neoplasm. PAPPA functions as a highly specific metalloproteinase cleaving IGF binding proteins (IGFBPs) ¡2, ¡4 and ¡5, thereby activating IGFs. 12, 13 It is tightly bound to membrane anchored glycosaminoglycans present on the cell surface. Cleavage of IGFBPs occurs in close proximity to the IGF1 receptor (IGF1R), increasing the IGF concentration at its binding site. 14, 15 IGF is one of the most prominent growth factors deposited in the bone matrix and bound to IGFBP4 it represents a key player in bone modeling. [16] [17] [18] PAPPA knockout mice are reduced in size by 40% as IGFBP4 effectively inhibits IGF-dependent mitogenesis in the fetus. 19 Apart from its role in bone metabolism, IGF is important for growth, differentiation and development in many if not all tissues. IGF1R is deregulated in many cancers types making it a promising therapeutic target. 2, 20 In ES, the IGF-1 pathway has been identified as an important growth factor and IGF1R monoclonal antibody therapy is clinically evaluated. [21] [22] [23] [24] [25] [26] In ES, deregulation of IGF1R expression is caused by the ES-specific EWS-FLI1 fusion oncogene. Upon IGF binding the PI3K/AKT/mTOR and MEK/ERK/MAPK pathways are mediating cell growth and tumorigenesis.
ES are highly malignant tumors. They are characterized by early metastases. ES were originally described by Ewing in 1921 as endothelioma of the bone. In 1985, we described a neuroectodermal histogenesis for ES and confirmed both the endothelial and the neuroectodermal signature by microarray analysis in 2004. 11 ES are molecularly defined by chromosomal translocations leading to EWS-ETS gene fusions. The translocation-derived chimeric transcription factors yield transactivation, transformation, and the malignant phenotype. 11, 31, 32 At diagnosis about 20% to 30% of patients have overt metastases in lung, bone, and/or bone marrow. 33 Patients who have been diagnosed with bone marrow metastases have a fatal outcome irrespective of therapy. 34 T cell receptor (TCR) affinity enhanced T cells have shown some efficacy in sarcomas. 35 However, TCR affinity enhancement may increase TCR cross reactivity with the risk of severe and even lethal T cell attach on critical organ function. [36] [37] [38] TCR allo-restriction circumvents the risks of TCR affinity enhancement in T-cell-based cancer immunotherapy. 39 In addition, there is evidence for a graft vs. tumor effect in ES, providing an additional rationale for the utilization of allorestricted T cells. 40.41,42 However, allogeneic donor lymphocyte infusion (DLI) lacks specificity. 43, 44 Here, we report on the generation of TCR transgenic T cells directed against the tumor-associated antigen (TAA) PAPPA overexpressed in ES.
Material and methods

Cell lines
SK-N-MC and TC-71 (both ES cell lines) were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ; Braunschweig, Germany). A673 (ES cells) were obtained from ATCC (LGC Standards GmbH, Wesel, Germany). The EW7 ES cell line was obtained from Olivier Delattre, Institut Curie, Paris. The TAP-deficient HLA Ã A02:01 C T2 cell line (somatic cell hybrid) was obtained from P. Cresswell (Yale University School of Medicine, New Haven, CT, USA). The HLA-A Ã 02:01 ¡ erythroid leukemia cell line K562 was a gift from A. Knuth and E. J€ ager (Krankenhaus Nordwest, Frankfurt, Germany). All cell lines were routinely tested for purity and mycoplasma contamination. Tumor cell lines were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS, Biochrom, Berlin, Germany), 100 U/mL penicillin, 100 mg/mL streptomycin, and 2 mM L-glutamine (all from Life Technologies). RPMI 1640 medium for LCL and T2 cells was supplemented with 1 mM sodium pyruvate and nonessential amino acids, additionally.
Isolation of PBMCs
Peripheral blood mononuclear cells (PBMCs) were isolated from human peripheral blood samples of healthy donors (obtained with IRB approval and informed consent from the DRK-Blutspendedienst Baden-W€ urttemberg-Hessen in Ulm, Germany) by centrifugation over Ficoll-Paque (GE Healthcare, Freiburg, Germany) according to the supplier's recommendations.
Generation of dendritic cells (DCs)
CD14
C cells were isolated from PBMCs with anti-human CD14 magnetic particles (BD Biosciences, Heidelberg, Germany) according to the manufacturer's instructions. Purity of cells was confirmed by flow cytometry on a FACS Calibur (BD Bioscience). Culture and maturation of CD14
C cells was done as described previously. 45 
Isolation of CD8
C T cells CD8 C T cells were isolated from human HLA-A Ã 02:01 ¡ PBMCs by negative isolation using a cocktail of biotin-conjugated non-CD8
C monoclonal antibodies and anti-biotin micro beads followed by column depletion according to manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). Purity of isolated CD8 C T cells was confirmed by flow cytometry.
In vitro priming of HLA-A Ã 02:01/PAPPA 1434 allo-restricted T cells
Mature DCs were re-suspended in T cell medium (AIM-V supplemented with 5% human AB serum, 2 mM L-glutamine, and 50 mL/mL gentamycin) and pulsed with selected peptides at a concentration of 30-50 mM in the presence of 20 mg/mL b1MG (Sigma, Taufkirchen, Germany) for 4 h at 37 C and 5% CO 2 . Pulsed cells were than washed and used for T cell priming as described previously. 45 Multimer-staining and cell sorting Two weeks after in vitro priming activated T cells were pooled and stained with specific peptide/HLA-A Ã 02:01-multimer-PE (PAPPA1434, IILPMNVTV) and CD8 C -FITC (BD Bioscience) for cell sorting. An unspecific peptide/HLA-A Ã 02:01-multimer-PE directed against LIPI (Lipase member I, LLNEEDMNV) served as a negative control. 46 Cell sorting was done on a FACS Aria (BD Bioscience).
Limiting dilution
After FACS sorting, multimer-PE-specific T cells were expanded using limiting dilution. Expansion was conducted in round-bottom 96-well plates in 200 mL T cell medium supplemented with anti-CD3 (30 ng/mL), rhIL-2 (100 U/mL), rhIL-15 (2 ng/mL); irradiated LCL (1£10 5 per well) and irradiated PBMCs pooled from three different donors (5 £ 10 4 per well) were used as feeder as previously described. 45 Cytokines and 100 mL medium/well were replaced after 1 week. Expanded T cells were further characterized in ELISpot assays.
Vb analysis of T cell receptor repertoire
To determine T cell clonality and Vb expression, the IOTest Ò Beta Mark Kit (Beckman Coulter, Brea, CA, USA) was used according to the manufacturer's protocol. This kit is designed for flow cytometric determination of the T cell repertoire (TCR) and covers about 70% of the normal human TCR Vb repertoire.
ELISpot assay
96-well mixed cellulose ester plates (MultiScreen-HA Filter Plate, 0.45 mm Millipore, Eschborn, Germany) and captureantibody solutions (all Mabtech, Hamburg, Germany) were used for IFNg and granzyme B ELISpot assays as described previously. 45 Spots in plates were counted on an AID-ELIRIFL04 ELISpot reader (Autoimmun Diagnostika, Strassberg, Germany). All experiments were performed in triplets with exception of the initial screening ELISpot.
xCELLigence proliferation assay
Cell proliferation was measured with an impedance-based instrument system (xCELLigence, Roche/ACEA Biosciences) enabling label-free real-time analysis. Briefly, 1 £ 10 4 to 2.5 £ 10 4 targets cells were seeded in 200 mL medium. During the exponential growth phase 100 mL was replaced by a 100 mL T cell suspension. Cellular impedance was measured periodically every 15 min after T cell addition.
Identification of TCR sequence
Primers for the identification of the TCR were used according to Schuster et al. 47 RNA from T cell clones was isolated via TRI Reagent Solution (Invitrogen). For cDNA synthesis, the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used according to manufactures protocol. TCR PCR was carried out using the AccuPrime TM Taq DNA Polymerase System (Invitrogen) and an Eppendorf Master Cycler. PCR reaction was done in twin.tec real-time PCR plate 96 (Eppendorf). Primers, PCR composition, and cycler settings were used as described previously. 48 PCR samples were loaded onto 1.5% agarose gels and run at 110 V for 50 min. 1 KB Plus DNA Ladder (Life Technologies) was used for size determination. PCR products at the expected sizes (370-500 bp for alpha chain and 190-290 bp for beta chain) were isolated with the StrataPrep Gel Extraction Kit (Agilent) and sent for sequencing (Sequiserve, Vaterstetten). Sequencing identified parts of the alpha and beta chains. New primers were implemented according to the predicted TCR sequence by IMGT/V-QUEST covering the whole sequence of the according alpha and beta chain (specific primers for PAPPA-2G6 TCR in 5 0 -3 0 direction: TRAV5 Ã 01: ATG AGG CAA GTG GCG AGA GTG AT; TRBV4-2 Ã 01 ATG GGC TGC AGG CTG CTC T). Sequence modifications were done to improve expression via codon optimization and minimal murinization for the PAPPA-2G6 TCR. 49 Both chains were linked via a P2A sequence. This construct was than synthesized and cloned into the MP71 vector (done by Gene Art, Life Technologies, Regensburg).
Transduction and isolation of CD8
C T cells 293T GalV virus producing cells were seeded at a concentration of 0.2£10 6 /well in 3 mL DMEM onto 6-well plates 24 h prior to transfection. Transfection of HLA-A Ã 02:01 ¡ PBMCs was performed using TransIT-293T according to manufacturer's manual. A
Ã 02:01 ¡ cells were used for the generation of TCR transgenic T cells given cross reactivity of HLA-A Ã 02:01 C cells with one more peptide. 200 mL of serum-free medium was placed into a 1.5 mL FACS tube. 9 mL of TransIT were added, vortexed, and incubated at RT for 20 min. 1 mg of TCR plasmid was added and mixed carefully. After 30 min incubation, the solution was added drop-wise onto the cells and incubated for 48 h at 37 C. Virus containing supernatant was collected, centrifuged at 1,000 g for 5 min and sterile filtered (0.45 mm). Virus was used fresh or stored at ¡80 C. PBMCs for viral transduction were isolated from Buffy coats and stimulated with 50 ng/mL OKT-3 and 100 U/mL rhIL-2 48 h prior to spin infection. The day before transduction non-treated 24-well plates were coated with 400 mL Retronectin Ò in PBS at a concentration of 12.5 mg/ mL and stored at 4 C. Directly before transduction the supernatant was removed. Wells were blocked with 2% BSA in PBS for 30 min at 37 C and washed twice with 2.5% HEPES in HBSS. Stimulated PBMCs were collected and set to a concentration of 1£10 6 /mL in TCM. 1 mL of each Virus and PBMCs were added into coated 24-well plates plus additional Protamine-sulfate (c end D 4 mg/mL), HEPES (c end D 0,5%), and IL-2 (c end D 100 U/mL). Plates were centrifuged for 90 min at 820 g in 32 C preheated centrifuge and stored at 37 C, 5% CO 2 overnight. The next day cells were harvested and split 1:1. Cells were again placed on coated 24-well plates with fresh virus plus additives and centrifuged at 820 g/90 min/32 C. Medium was replaced after 48 h and transduction efficiency was checked after 72 h via FACS multimer staining. TCR transgenic T cells were isolated via magnetic anti-PE microbeads according to manufacturers manual (Miltenyi). Isolated cells were then cultured using irradiated mixed PBMCs and LCLs as feeder cells.
In vivo validation of TCR transgenic T cell efficacy
Immune deficient Rag2 C -FITC (both BD), and multimer-PE antibodies and measured using a BD FACSCalibur TM .
Immunohistochemistry
Histological analyses were performed on formalin fixed, paraffin-embedded samples. All tissue slides were collected at the Department of Pathology of the Ludwig-Maximilians Universit€ at M€ unchen. The following primary antibodies were used: CD8 C (1:100, SP16, DCS) and PAPPA (1:50, HPA001667, Sigma Aldrich)
Statistical analysis
Descriptive statistics were used to determine mean and standard deviation of the mean (SD). Differences were analyzed by unpaired two-tailed Student's t-test using either Excel (Microsoft) or Prism 5 (GraphPad Software); p values < 0.05 were considered statistically significant ( Ã p < 0.05; ÃÃ p < 0.005; ÃÃÃ p < 0.0005).
Results
Identification of PAPPA-derived peptides for allogeneic T cell priming PAPPA is highly overexpressed in ES in contrast to normal tissue in RNA microarrays and in relation to other tumor entities (Figs. S1A and B) . Suitable peptides for in vitro priming were selected after SYFPEITHY in silico prediction. The six peptides with the highest predicted binding affinities were loaded onto tap deficient T2 cells and measured for MHC I stabilization (Fig. S1C) . In titrations, the PAPPA 1434 peptide was identified as the most potent peptide and therefore chosen for further T cell in vitro priming (Fig. 1A) . 
ES specificity of PAPPA-2G6 T cells
The isolated T cell clone PAPPA-2G6 specifically recognizes PAPPA 1434 peptide (T2C) when loaded on T2 cells in contrast to influenza (T2¡) negative control (Fig. 1B) . Reactivity was concentration dependent as shown in the T2 titration assay (Fig. 1C) . Furthermore, specific reactivity toward A673, TC-71, and EW7 (all HLA-A Ã 02:01 C ) was observed, whereas the ES HLA-A Ã 02:01 ¡ cell line SK-N-MC was not recognized. The MHC ¡ cell line K562 served as a NK cell control and was also not recognized (Fig. 1D) . Specific lysis of A673 target cells was shown for PAPPA-2G6 T cells in xCELLigence assay. SK-N-MC cells (A2 ¡ ) served as a negative control and were not affected, whereas A673 ES cells were effectively lysed (Fig. 1E) .
Identification of the PAPPA-2G6 TCR sequence
To identify the Vb-chain of the TCR-clone the IOTest Ò Beta Mark Kit was used and indicated the expression of Vb7.2 (Fig. S2A) . Flow cytometry results were further confirmed via PCR (Fig. S2B) . The PCR product was sequenced, analyzed via IMGT/V-Quest research, and confirmed the sequence of the TRBV4-2 Ã 01F Vb-chain. For the screening of the Va-chain the PCR revealed initially three different PCR products, which were further sequenced (Fig. S2C) . However, IMGT/V-Quest analysis predicted only the TRVA5 Ã 01F as the native Va-chain sequence. New specific primers directed against both identified variable chains were used to amplify the whole Va/b-chains (Fig. 2) and for further construction of the retroviral vector after sequencing.
ES reactivity of PAPPA-2G6 TCR transgenic T cells
After retroviral transduction PAPPA-2G6 TCR transgenic T cells were isolated via multimer labeling and magnetic bead separation and cultured for further analysis (Fig. 3A) . In IFNg ELISpot assays specificity of the TCR transgenic T cells toward T2 cells pulsed with the PAPPA 1434 peptide was maintained in contrast to the influenza control peptide (Fig. 3B) . Also, in T2 peptide titrations the sensitivity of the TCR toward the peptide pulsed T2 cells remained comparable to the original T cell clone (Fig. 3C) . In addition, HLA-A Ã 02:01 C ES cell lines A673, TC-71, and EW7 were similarly recognized in contrast to the HLA-A2 ¡ ES cell lines SK-N-MC and SB-KMS-KS1 (Fig. 3D) . Furthermore, PAPPA-specific T cells specifically lysed A673 cell lines in xCELLigence assay in contrast to SK-N-MC controls (Fig. 3E) .
Reduced tumor burden after application of PAPPA-2G6 TCR transgenic T cells
Prior to adoptive transfer T cell were checked for phenotypic markers. T cells showed a CD45RO
CCC , CD62L CC , CCR7 dim , and CD45RA
C phenotype with features of central memory (T CM ) as well as effector memory (T EM ) T cells (Fig. 4A) .
Mice in all groups received s.c. inoculated A673 cells and a total body irradiation (3.5 Gy) on day 3. Additionally, 1.5£10 7 irradiated IL15-secreting NSO cells were injected twice per week i.p. T cells were applied on day 4. The control groups were either untreated (n D 6), received 5£10 6 CD8 C depleted PBMCs (n D 6) or 5£10 6 CD8 C depleted PBMCs substituted with 5£10 6 unspecific T cells (n D 5). The study group received 5£10 6 CD8 C depleted PBMCs substituted with 5£10 6 specific PAPPA-2G6 TCR transgenic T cells (n D 14). Only the study group that was treated with the TCR transgenic T cells showed a significant weight reduction in contrast to the controls whereas the control groups showed no reduction in tumor growth (Fig. 4B) .
Detection of TCR transgenic T cells in blood, bone marrow, and tumor samples
Samples from blood, bone marrow, and tumors of sacrificed mice were stained by CD8
C mAB and MHC-multimers to detect PAPPA-specific T cells (mice 1-3, Fig. 5 ). Via flow cytometry T cells were detectable in all three types of tissue. Yet, T cell infiltration into the tumor site was greater in the study group treated with the TCR transgenic T cells in comparison to the control group treated with unspecific T cells (mice 4-6, Fig. S3 ). Figure 2 . Identification of the PAPPA-2G6 TCR sequence. Full TCR PCR with specific primers for TRAV5 and TRBV4-4. PCR products (green boxes) of expected sizes were extracted and sequenced.
Immunohistochemistry reveals tumor-infiltrating T cells and PAPPA positivity in A673 xenografts
Tumor-infiltrating T cells were detected in A673 tumors with a specific CD8
C antibody (Fig. 6A) . Unspecific T cells of the control group were less frequently detected at the tumor site in contrast to the PAPPA-2G6-treated mice. Furthermore, we showed PAPPA expression in A673 xenografts (Fig. 6B ) in contrast to adjacent normal murine tissue. Placental tissue served as a positive control.
Discussion
Insulin and IGF pathways represent widely investigated mechanisms and targets in cancer. 50 The IGF-axis plays an important role in pediatric cancer in general and ES in 
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particular.
1,2,28,29 Pre-clinical and clinical studies addressing the IGF axis revealed IGF1R pathway inhibition as a promising treatment strategy. 51, 52 Variations of this strategy remain to be investigated, 53, 54 in particular those that may be capable of overcoming resistance against IGF1R antibodies. One of these could be to decrease IGF concentration by targeting PAPPA to prevent IGF from binding to alternate receptors, e.g., the insulin receptor. In addition, utilization of antigens present in pregnancy privileged sites as therapeutic targets in cancer have recently gained renewed interest. 3 PAPPA expression has been associated with various epithelial cancers. [4] [5] [6] [7] [8] [9] [10] We previously showed its overexpression in ES.
11 PAPPA functions as a highly specific metalloproteinase cleaving IGF binding protein-4 (IGFBP-4) thereby activating IGFs. Of note for bone cancer, it is critically involved in bone growth. 55 PAPPA is an important factor for growth in ES as recently shown by knockout assays in ES cells. In vitro ES growth was hampered and in vivo survival of ES-bearing mice was prolonged. 56 Targeting the IGF pathway via PAPPA may thus represent a novel option for PAPPA positive bone sarcoma, in particular for advanced ES patients.
The recent breakthroughs using by T cell checkpoint inhibitors and CARs has renewed the interest in immunotherapy of cancer. 57 In our study, we first isolated T cells specific for the PAPPA 1434 peptide (IILPMNVTV) and introduced its TCR retrovirally into random T cells. To ensure specific pairing of the transgenic TCR, we performed minimal murinization in addition to codon optimization for increased homologous pairing and expression in human T cells. 49 Next, we showed ES specificity of this TCR in vitro. Then, we demonstrated comparable peptide affinities of wild type and transgenic TCR as well as ES specificity. Finally, we demonstrated in vivo efficacy against 
human ES in Rag2
¡/¡ gc ¡/¡ mice. PAPPA-2G6 TCR transgenic T cells proved to be effective and no in vivo adverse effects were observed. Of interest, we observed a larger amount of infiltrating T cells into the tumor site in mice treated with the PAPPA-2G6 TCR transgenic T cells as compared to the unspecific T cell control group. In vivo efficacy may further be improved by applying certain T cell subtypes, e.g., T CM or T SCM or by using a more efficient mouse strand for T cell engraftment. [58] [59] [60] [61] Yet in our studies, we could demonstrate T cell engraftment in treated mice. Functionality of ex vivo T cells remains to be shown in future studies. Given our recent finding that, irrespective of treatment, bone marrow involvement determines fatal outcome in ES patients, our finding of ES-specific T cell infiltration into the bone marrow is of particular interest. It may open new treatment options for these dismal patients. 62 To the best of our knowledge, this is the first study upon PAPPA in ES and the first successful attempt to target PAPPA via TCR transgenic T cells. In contrast to chimeric antigen receptor (CAR) bearing T cells, TCR-based T cell therapy is not restricted to surface molecules. Rather, TCR employing T cells can target peptides derived from all proteins required for malignancy and metastasis. TCR-based recognition is restricted to MHC, whereas CAR T cell action is MHC independent, making this approach easily accessible to a wider range of patients. 63 However, selection of a target that is not dispensable for malignancy is critical for avoidance of resistance evolution and success of targeted therapies. This applies in particular to oligo-mutated malignancies such as ES, where checkpoint inhibitors are not efficacious.
In other tumor entities, feasibility of targeting PAPPA via antibodies already has been demonstrated. 64 However, PAPPA is not internalized into the tumor cell and may rather be cleaved on the cell surface resulting in free-floating PAPPA/ antibody complexes in the blood stream. The immunological synapse between TCR and MHC is about 15 nm wide. 65 PAPPA in its active form is covalently bound to glycosaminoglycans on the cell surface. 14, 15 This type of binding is giving PAPPA a spacer function possibly advantageous for its function, i.e., capturing IGFBP-4/IGF complexes for cleavage and thereby activating IGFs. While the distance between a CAR and its target is not clearly defined, the spacer PAPPA will increase this distance and may reduce CAR efficacy 14,66 making a TCR-based approach more attractive. Furthermore, circulating inactive PAPPA bound to the pro-form of eosinophil major basic protein (proMBP) in the blood may non-specifically activate CAR T cells causing a cytokine release syndrome. 67, 68 A drawback of TCR-based T cell therapy is potential cross reactivity of the TCR with unknown target structures. While CARs are not tumor specific, their cross reactivity with normal cells is defined. In contrast, a TCR may have cross reactivity with an unknown target. This risk of cross reactivity is greatly enhanced by TCR affinity enhancement, an approach utilized by expert groups in the TCR-based immunotherapy field to enhance affinity and avidity of the TCR against the tumor target.
36-38 Distinct from TCR affinity enhancement, we addressed the challenge of reconciling efficacy with specificity by generating allo-restricted TCRs against a tumor-specific peptide. 39, 69 Taken together, these considerations in conjunction with the data reported here may render TCR transgenic T cells a promising approach to target PAPPA expressing malignancies, in particular ES.
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